U
SRPT icon

UBS’s Sarepta Therapeutics SRPT Stock Holding History

UBS’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$1.28M Buy
60,900
+57,800
+1,865% +$1.3M ﹤0.01% 3346
2014
Q2 		$92K Sell
3,100
-15,900
-84% -$503K ﹤0.01% 6036
2014
Q1 		$457K Buy
19,000
+3,900
+26% +$99.4K ﹤0.01% 4330
2013
Q4 		$308K Buy
15,100
+900
+6% +$26.7K ﹤0.01% 4829
2013
Q3 		$671K Buy
14,200
+4,200
+42% +$162K ﹤0.01% 3787
2013
Q2 		$380K Buy
+10,000
New +$358K ﹤0.01% 4367

Other funds holding SRPT

CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

UBS's SRPT Position: Q3 2014 in Review

UBS reduced its Sarepta Therapeutics (SRPT) stake by 1.4% in Q3 2014, selling an estimated $23.7K and leaving 74,389 shares worth $1.57M. The position accounts for ﹤0.01% of the portfolio, ranked #3139.

UBS first reported a position in SRPT in Q2 2013 and has held it in 6 quarters since. The position peaked at $5.42M in Q2 2013. 123 funds tracked by Wall St. Rank hold SRPT as of Q3 2014.

  • UBS held 74,389 shares of Sarepta Therapeutics worth $1.57M as of Q3 2014.
  • UBS sold 1,049 Sarepta Therapeutics shares in Q3 2014, an estimated $23.7K.
  • Sarepta Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #3139 holding.
  • UBS first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 6 quarters since.
  • UBS's Sarepta Therapeutics position peaked at $5.42M in Q2 2013.
  • 123 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.